Silver Book Fact

Cost-effectiveness of flu vaccine

Vaccination for pandemic influenza (pH1N1) prior to an outbreak produces incremental cost-effectiveness ratios for individuals without high risk conditions, ranging from $8,000 to $52,000 per quality-adjusted life year.

Prosser L, Lavelle T, Fiore A, Bridges C, et al. Cost-Effectiveness of 2009 Pandemic Influenza A (H1N1) Vaccination in the United States. PLoS ONE. 2011; 6(7). http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0022308

Reference

Title
Cost-Effectiveness of 2009 Pandemic Influenza A (H1N1) Vaccination in the United States
Publication
PLoS ONE
Publication Date
2011
Authors
Prosser L, Lavelle T, Fiore A, Bridges C, et al
Volume & Issue
Volume 6, Issue 7
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Economic Value
  • Future Value

Related Facts

  • Potential value of pneumonia vaccine
    Use of PCV13 (13-valent pneumococcal conjugate vaccine) in older adults is estimated to have the potential to reduce total healthcare costs by $3.5 billion and total societal costs by $7.4…  
  • Use of shingles vaccines significantly reduced disease burden
    Use of a live attenuated VZV (varicella-zoster vaccine) in a randomized trial reduced the burden of illness from shingles by 61.1% and the incidence of postherpetic neuralgia (PHN) by 66.5%.  
  • Infection control program reduced hospital-acquired HAIs by > 1/3
    A multimodal infection control program reduced the rate of hospital-acquired HAIs by more than 1/3 and improved quality of care and patient outcomes.  
  • Over 6 years, flu vaccine prevented >110,000 hospitalizations and 5.8 million medical visits
    Over a 6-year period (2005 – 2011), the influenza vaccine prevented more than 110,000 hospitalizations and 5.8 million medical visits.  
  • Negative value of antibiotics to drug companies
    The value of an antibiotic to a drug company is negative $50 million- compared to the positive value of $1 billion for a new musculoskeletal drug.